Neurocrine Biosciences, Inc. (NBIX) Insider Sells $422,702.00 in Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Christopher Flint Obrien sold 6,925 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the transaction, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Christopher Flint Obrien also recently made the following trade(s):
- On Tuesday, September 5th, Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $57.50, for a total value of $3,036,977.50.
- On Thursday, July 27th, Christopher Flint Obrien sold 8,734 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $50.00, for a total value of $436,700.00.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded up 0.19% on Tuesday, reaching $61.94. 677,413 shares of the company were exchanged. The company’s market cap is $5.46 billion. The company’s 50-day moving average price is $56.42 and its 200 day moving average price is $50.19. Neurocrine Biosciences, Inc. has a 12 month low of $37.35 and a 12 month high of $62.90.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same period in the prior year, the firm posted ($0.46) EPS. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post ($2.44) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $422,702.00 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/03/neurocrine-biosciences-inc-nbix-insider-sells-422702-00-in-stock.html.
Several institutional investors have recently made changes to their positions in NBIX. Teacher Retirement System of Texas grew its stake in Neurocrine Biosciences by 0.8% during the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after purchasing an additional 57 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares during the period. Utah Retirement Systems lifted its stake in Neurocrine Biosciences by 1.9% in the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after buying an additional 300 shares during the period. Schroder Investment Management Group lifted its stake in Neurocrine Biosciences by 1.7% in the first quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock valued at $856,000 after buying an additional 335 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in Neurocrine Biosciences by 5.6% in the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after buying an additional 763 shares during the period.
Several brokerages have recently issued reports on NBIX. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Cowen and Company reiterated an “outperform” rating and issued a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Neurocrine Biosciences currently has an average rating of “Buy” and an average target price of $68.44.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.